Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046820 · ClinicalTrials.gov registry record · Phase 3
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
A Phase 3 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets, sponsored by Inozyme Pharma.
- Active
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 15
- Study locations
NCT06046820 is a Phase 3 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets that is active but no longer recruiting, run by Inozyme Pharma. The registered enrollment target is 27 participants, below the 75-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (64% lower). The trial reports 15 study locations across 7 states.
The verdict
NCT06046820, a Phase 3 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets, is active but no longer recruiting, sponsored by Inozyme Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
Conditions Studied
Interventions
- DRUG INZ-701
- DRUG Control Arm (Conventional Therapy)
Study Locations (15)
Other
- Queensland Children's Hospital - South Brisbane
- Centre Hospitalier Universitaire (CHU) Sainte-Justine - Montreal
- Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department) - Le Kremlin-Bicêtre
- King Faisal Specialist Hospital and Research Centre - Riyadh
- Hospital San Joan de Deu - Barcelona
- Umraniye Training and Research Hospital - Istanbul
- Cukurova Universitesi Tip Fakultesi - Sarıçam
- Al Jalila Children's Specialty Hospital - Dubai
- Royal Manchester Children's Hospital - Manchester
Colorado
- Children's Hospital of Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-11-05 |
| Est. Completion | 2026-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046820
The ClinicalTrials.gov registry entry for NCT06046820 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 75-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (64% lower). The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 2 interventions - of which INZ-701 is the first listed.
NCT06046820 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Other, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT06046820 about?
NCT06046820 is a clinical study titled "The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency". The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
What is the current status of trial NCT06046820?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2023-11-05. Estimated completion is 2026-02.
What conditions does trial NCT06046820 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy.
What interventions are being tested in trial NCT06046820?
The interventions under investigation include: INZ-701 (DRUG), Control Arm (Conventional Therapy) (DRUG).
Who is sponsoring clinical trial NCT06046820?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046820 being conducted?
This trial has 15 study locations across Colorado, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
COMPLETED · Phase 1
Explore more on PlainTrial
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
All registered trials for this condition
Autosomal Recessive Hypophosphatemic Rickets
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.